Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 8 clinical trials
Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy (RIVA-PSP)

strategies in PSP. Trials of cholinesterase inhibitors in PSP have produced rather conflicting results: donepezil improves cognition but deteriorates some motor functions whereas a case series of 5

mini-mental state examination
screening procedures
donepezil
parkinson's disease
dopa
  • 203 views
  • 23 Feb, 2022
  • 1 location
CHIEF PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease) (CHIEF PD)

has the potential to almost halve the number of falls. This trial aims to definitively determine whether cholinesterase inhibitors (ChEi), can prevent falls in Parkinson's and whether this

dopamine
  • 37 views
  • 23 Feb, 2022
  • 27 locations
Does Higher OT Temperature and IV Ondansetron Reduce Incidence of PSS in Parturients?

This study will look at the incidence of post-spinal shivering (PSS) among the obstetrics population and will investigate whether higher operation theater (OT) temperature range or/and IV Ondansetron are able to reduce the incidence of PSS. This is a double-blind, randomized, factorial study, patients will be grouped into 4 groups …

Accepts healthy volunteers
  • 0 views
  • 21 Oct, 2021
  • 1 location
tDCS on Parkinson's Disease Cognition (tDCS-PD-fMRI)

dysfunction is one of the most significant factors affecting the quality of life of patients with PD. While dementia in Parkinson's disease is routinely treated by cholinesterase inhibitors (e.g., donepezil

cholinesterase inhibitors
movement disorder
motor symptoms
dementia
antipsychotics
  • 165 views
  • 20 Apr, 2022
  • 1 location
Cortical Excitability in AD-AHeAD

The aim of this study is to understand the relationship between brain excitability, neuroimaging, and cognitive function in early Alzheimer's disease in order to help develop future treatments. Participants are followed over 18 months.

  • 0 views
  • 03 Mar, 2022
  • 1 location
Senolytic Therapy to Modulate Progression of Alzheimer's Disease (SToMP-AD)

The purpose of this pilot study is to evaluate whether a combination of two drugs, dasatinib (D) and quercetin (Q) [D+Q], penetrate the brain using cerebrospinal fluid (CSF) in older adults with early Alzheimer's disease (AD). This combination of drug therapy has been shown to affect dying cells in humans …

body mass index
alzheimer's disease
cholinesterase inhibitors
dementia
progression of alzheimer's disease
  • 9 views
  • 24 Jan, 2022
  • 1 location
Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder

Overactive bladder is more prevalent among the Sjogren syndrome's population compare to the general population. Both anti-muscarinic agent and beta-3 agonist are recommended as second line treatment for overactive bladder syndrome. However, theoretically, undesirable effect of the anti-muscarinic agent such as dry mouth and constipation would make it less suitable …

  • 0 views
  • 20 Aug, 2021
  • 1 location
Spinal Cord sTimulation thEraPy for Parkinson's Disease Patients With Gait Problems (STEP-PD)

Gait difficulties are common in Parkinson's disease (PD) and cause significant disability. No treatment is available for these symptoms. Spinal Cord Stimulation (SCS) has been found to improve gait, including freezing of gait, in a small number of PD patients. The mechanism of action is unclear and some patients are …

  • 0 views
  • 05 May, 2022
  • 1 location